Amarin Corp. ADR Stock

Description Amarin

Amarin Corporation (AMRN) is a biopharmaceutical company that specializes in developing and commercializing drugs to improve cardiovascular health. Specifically, they focus on developing therapies for patients who need to lower their triglyceride levels to reduce the risk of heart disease. Amarin's flagship product is Vascepa, a prescription-grade omega-3 fatty acid pill that has been shown to reduce triglyceride levels as well as other cardiovascular benefits. Vascepa was approved by the FDA in 2012 and has been marketed aggressively by Amarin since then. The company has also been exploring other uses for omega-3 fatty acids in potential future medications. Amarin is headquartered in Dublin, Ireland, but has operations in the United States and other countries. As of August 2021, the stock price for AMRN was around $5 per share.

Competitors of Amarin

Amarin is a biopharmaceutical company that specializes in the development and commercialization of drugs for the treatment of cardiovascular diseases. Its primary product is Vascepa, a prescription omega-3 fatty acid drug that has been approved by the FDA for the treatment of severe hypertriglyceridemia.

The most important competitors of Amarin in the pharmaceutical industry include:

1. GlaxoSmithKline: A British multinational pharmaceutical company that produces a range of prescription medications, including drugs used in the treatment of cardiovascular diseases such as high blood pressure, high cholesterol, and heart disease.

2. Pfizer Inc.: An American multinational pharmaceutical corporation that develops and produces a broad range of prescription drugs, including cholesterol-lowering drugs and cardiovascular drugs.

3. AstraZeneca: A British-Swedish multinational pharmaceutical company that produces a range of prescription drugs, including drugs used in the treatment of cardiovascular diseases such as high blood pressure, high cholesterol, and heart disease.

4. Eli Lilly and Company: An American pharmaceutical company that develops and produces a range of prescription drugs, including cardiovascular drugs such as blood thinners and drugs used in the treatment of high cholesterol.

5. Novartis: A Swiss pharmaceutical company that produces a range of prescription drugs, including cardiovascular drugs such as blood pressure medications and drugs used in the treatment of heart disease.

These companies are Amarin's main competitors in the pharmaceutical industry and may offer similar drugs to Vascepa or other treatments for cardiovascular diseases, which could impact Amarin's market share and financial performance.